SAGE Therapeutics Inc. (SAGE) Is Soaring To A New High On Study Results

Shutterstock photo

(RTTNews.com) - SAGE Therapeutics Inc. ( SAGE ) announced Thursday morning that its Phase 2 study of SAGE-217 showed a statistically significant mean reduction in the Hamilton Rating Scale for Depression.

SAGE Therapeutics has gapped open dramatically higher this morning and is now up 71.24 at $163.14 on above average volume. The stock has soared to a new high for the year.

For comments and feedback: contact editorial@rttnews.com

This article appears in: Stocks , Politics
Referenced Symbols: SAGE

More from RTT News


See headlines for SAGE

Research Brokers before you trade

Want to trade FX?